ArticleBiomedicines2022
FIB-4 Index and Neutrophil-to-Lymphocyte-Ratio as Death Predictor in Coronary Artery Disease Patients.
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- FIB-4, a surrogate marker of liver fibrosis, predicts mortality and adverse events after acute myocardial ınfarction.Internal and emergency medicine · 2026Observational
- FIB-4 predicts coronary disease and early outcomes in unstable angina pectoris.Internal and emergency medicine · 2026Article
- Prognostic value of the fibrosis-4 index for predicting in-hospital mortality in sepsis patients: evidence from MIMIC-IV and eICU databases.Scientific reports · 2026Article
- The relationship between the Fibrosis-4 (FIB-4) index, occurrence of contrast-induced nephropathy, and prognosis after percutaneous coronary intervention in acute coronary syndromes.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
- Unveiling the prognostic power of FIB-4 index: a new frontier in heart failure mortality.European journal of medical research · 2025Article
- Comparative prognostic performance of the FIB-4 index versus SYNTAX and GRACE scores in predicting major cardiovascular events in acute coronary syndrome.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- Relationship Between Frontal QRS-T Angle and Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score in Patients with Stable Angina Pectoris.Journal of clinical medicine · 2025Article
- Mutual Effect of Nutritional Status and Inflammatory Processon Mortality after Superficial Artery Intervention: NAPLES Score.Acta Cardiologica Sinica · 2025Article
- Association between inflammatory burden index and prognosis in patients with coronary heart disease: A retrospective study.PloS one · 2025Article
- FIB-4 index is associated with mortality in critically ill patients with alcohol use disorder: Analysis from the MIMIC-IV database.Addiction biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD)-associated liver fibrosis is likely related to coronary artery disease (CAD) by the mediation of systemic inflammation. This study aimed at evaluating the predictive value of neutrophil-to-lymphocyte-ratio (NLR) and fibrosis-4 index (FIB-4), indices of inflammation and fibrosis, respectively, on CAD mortality. Data from 1460 CAD patients (1151 males, age: 68 ± 10 years, mean ± SD) were retrospectively analyzed. Over a median follow-up of 26 months (interquartile range (IQR) 12−45), 94 deaths were recorded. Kaplan−Meier survival analysis revealed worse outcomes in patients with elevation of one or both biomarkers (FIB-4 > 3.25 or/and NLR > 2.04, log-rank p-value < 0.001). In multivariate Cox regression analysis, the elevation of one biomarker (NLR or FIB-4) still confers a significant independent risk for mortality (hazard ratio (HR) = 1.7, 95% confidence interval (95% CI): 1.1−2.7, p = 0.023), whereas an increase in both biomarkers confers a risk corresponding to HR = 3.5 (95% CI: 1.6−7.8, p = 0.002). Categorization of patients with elevated FIB-4/NLR could provide valuable information for risk stratification and reduction of residual risk in CAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.